DOUG:NYSEDouglas Elliman Inc. Analysis
Data as of 2026-07-27 - not real-time
$1.74
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Douglas Elliman (DOUG) is trading at $1.74, well below its 20‑day ($1.85) and 50‑day ($1.79) simple moving averages and also under its 200‑day SMA ($2.19), indicating a bearish technical backdrop. The RSI sits at 43, the MACD histogram is negative and the signal line is bearish, while volume is on a downtrend, all of which reinforce short‑term downside pressure. At the same time, the stock exhibits high volatility (43% 30‑day) and a beta of ~1.8, suggesting amplified moves relative to the market and a heightened risk profile. Despite a trailing P/E of 34.8 that exceeds the industry average of 32.9, the forward P/E of 19.3 and a DCF‑derived fair value of $3.28 imply that the market may be undervaluing the company, as the current price is roughly half of the intrinsic estimate. Revenue has contracted 15% YoY and operating margins remain negative, yet free cash flow is positive and the price‑to‑book ratio is below 1 (0.91), hinting at a potential value cushion.
The most material catalyst this week is the announcement of a sweeping AI transformation built on Google Cloud, which triggered a 12.3% pre‑market sell‑off. While the AI initiative could eventually lower costs and modernize the brokerage model, the immediate market reaction reflects investor skepticism about execution risk. Coupled with a historic max drawdown of nearly 50% and a modest ROE of 2.6%, the stock faces considerable upside potential if the strategic shift bears fruit, but the path forward remains uncertain.
The most material catalyst this week is the announcement of a sweeping AI transformation built on Google Cloud, which triggered a 12.3% pre‑market sell‑off. While the AI initiative could eventually lower costs and modernize the brokerage model, the immediate market reaction reflects investor skepticism about execution risk. Coupled with a historic max drawdown of nearly 50% and a modest ROE of 2.6%, the stock faces considerable upside potential if the strategic shift bears fruit, but the path forward remains uncertain.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish technical indicators (price below SMAs, negative MACD)
- Recent 12.3% pre‑market price drop on AI news
- High volatility and decreasing volume
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- DCF fair value indicates ~80% upside potential
- Forward P/E compression suggests earnings improvement
- Strategic AI rollout could improve margins if executed
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to book and DCF estimates
- Low price‑to‑sales and price‑to‑book ratios
- Potential long‑term competitive advantage from technology integration
Key Metrics & Analysis
Financial Health
Revenue Growth-15.40%
Profit Margin0.50%
P/E Ratio34.8
ROE2.65%
ROA-3.01%
Debt/Equity60.57
P/B Ratio0.9
Op. Cash Flow$-27603000
Free Cash Flow$23.6M
Industry P/E32.9
Technical Analysis
TrendNeutral
RSI43.1
Support$1.68
Resistance$2.05
MA 20$1.85
MA 50$1.79
MA 200$2.19
MACDBearish
VolumeDecreasing
Fear & Greed Index88.09
Valuation
Fair Value$3.28
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.80
Volatility43.16%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.